Blocking SETD2 Enhances the Therapeutic Efficiency of Menin Inhibitor in MLL ‐Fusion Leukemia
Cancer Science · 2026-08 · 117 (8) · 2221-2235
DOI: 10.1111/cas.70419 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 22.05.2026. Verfasst von Anpei Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Sciences, School of Medicine, Xiamen University, Xiamen, Fujian, China. Hauptthemen laut MEDLINE: Histone-Lysine N-Methyltransferase, Myeloid-Lymphoid Leukemia Protein, Proto-Oncogene Proteins, Oncogene Proteins, Fusion. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Fujian Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
During transcriptional elongation, the histone methyltransferase SETD2 binds to RNA polymerase II and deposits trimethylation marks at histone H3 lysine 36 (H3K36me3). However, the role of SETD2 in MLL‐ fusion leukemia has remained controversial over the past decade. Here, through genotyping of loss‐of‐function SETD2 mutations, we define the genetic basis for SETD2 acting as a haploinsufficient tumor suppressor in this disease. Then, we demonstrate that gene amplification and high expression of SETD2 are associated with poor prognosis, supporting the double‐sided roles of SETD2 in this kind of acute leukemia. Next, we show that inhibitors of SETD2 (EZM0414) and menin (Revumenib) have synergistic efficacy against MLL ‐fusion and NPM1 ‐mut leukemia and make prominent induction of cell cycle arrest, differentiation, and apoptosis. Moreover, SETD2 inhibition sensitizes leukemia cells to menin inhibitor through decreasing H3K36me3 marks, and combination therapy dramatically inhibits transcription of the canonical targeted genes, whose function may account for these phenotypic changes. The mode of action of this combined treatment is due to the attenuated both H3K36me3 at gene body regions and H3K4me3 at gene promoter regions. Finally, we clarify that the combined‐drug treatment delays MLL ‐fusion leukemia progression in vivo. Taken together, these findings establish the simultaneously blocking of transcription elongation and initiation by epigenetic inhibitors as a promising therapeutic strategy for these aggressive leukemias.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Basic Medical Sciences, School of Medicine, Xiamen University, Xiamen, Fujian, China.
- Department of Obstetrics and Gynecology, Zhongshan Hospital of Xiamen University, Xiamen, Fujian, China.
- Department of Nephrology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, China.
- School of Public Health, Beihua University, Jilin, China.
ORCID-Profile: Guanghui Jin, Bin Xu
Förderung
- Natural Science Foundation of Fujian Province
- National Natural Science Foundation of China
Zitieren
APA
Li, A., Zhang, Y., Li, Z., Liu, A., Zhang, L., Gao, S., Lin, X., Liu, X., Li, H., Jin, G., & Xu, B. (2026). Blocking SETD2 Enhances the Therapeutic Efficiency of Menin Inhibitor in MLL ‐Fusion Leukemia. Cancer Science, 117(8), 2221-2235. https://doi.org/10.1111/cas.70419
Vancouver
Li A, Zhang Y, Li Z, Liu A, Zhang L, Gao S, et al. Blocking SETD2 Enhances the Therapeutic Efficiency of Menin Inhibitor in MLL ‐Fusion Leukemia. Cancer Science. 2026;117(8):2221-2235. doi:10.1111/cas.70419
BibTeX
@article{Li2026,
author = {Li, Anpei and Zhang, Yuan and Li, Ziwei and Liu, Anhao and Zhang, Li and Gao, Shubin and Lin, Xiao and Liu, Xiaoming and Li, Huan and Jin, Guanghui and Xu, Bin},
title = {Blocking SETD2 Enhances the Therapeutic Efficiency of Menin Inhibitor in MLL ‐Fusion Leukemia},
journal = {Cancer Science},
year = {2026},
volume = {117},
number = {8},
pages = {2221--2235},
doi = {10.1111/cas.70419}
}
EUVIMED